News

AstraZeneca and Daiichi Sankyo’s Datroway Approved to Treat Non-Small Cell Lung Cancer in U.S.
The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...
AstraZeneca (AZN) Scores FDA Approval for Datroway, First TROP2 ADC for Lung Cancer
AstraZeneca PLC (NASDAQ:AZN) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company announced ...
Drug Store News8d
AstraZeneca, Daiichi Sankyo obtain FDA nod for Datroway
Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.
FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer
FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due.
Nasdaq16d
DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer - Nasdaq
DATROWAY is a specifically engineered TROP2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.
Investing.com Canada16d
Approval for AstraZeneca’s Datroway drug a ’minor positive’ for shares: JPMorgan
Investing.com -- AstraZeneca (NASDAQ: AZN) on Monday night received accelerated approval from the U.S. Food and Drug ...
AstraZeneca's Datroway gets green light from FDA
Drugmaker AstraZeneca's Datroway has been approved in the US for adult patients with previously treated advanced EGFR-mutated non-small cell lung cancer.
Wall Street Journal16d
AstraZeneca and Daiichi Sankyo’s Datroway Approved to Treat Non-Small ...
AstraZeneca and Daiichi Sankyo’s Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer. British pharmaceutical company AstraZeneca said Tuesday that ...